Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-Works Technologies AB has the GF Score of 68, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Bio-Works Technologies AB
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Bio-Works Technologies AB (XSAT:BIOWKS) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Bio-Works Technologies AB GF Score Related Terms
XSAT:BIOWKS vs ISRG, BDX, MDLN: GF Score Comparison
For the Medical Instruments & Supplies subindustry, Bio-Works Technologies AB's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Works Technologies AB GF Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Works Technologies AB's GF Score distribution charts can be found below:
* The bar in red indicates where Bio-Works Technologies AB's GF Score falls into.
Bio-Works Technologies AB (XSAT:BIOWKS) has a GF Score of 68 as of Aug. 22, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Bio-Works Technologies AB and its competitors. This is 19% above median its historical median of 57.00. Over the past decade, Bio-Works Technologies AB's GF Score has ranged from 7.00 to 80.00.
Is Bio-Works Technologies AB's GF Score too high?
Bio-Works Technologies AB's current GF Score of 68 is 19% above median its 10-year median of 57.00. Over the past 10 years, this metric has ranged from a low of 7.00 to a high of 80.00. Overall, Bio-Works Technologies AB has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Works Technologies AB's GF Score compare to ISRG and BDX?
Bio-Works Technologies AB's GF Score of 68 can be compared against companies in the Medical Devices & Instruments industry. Historically, Bio-Works Technologies AB's own GF Score has ranged from 7.00 to 80.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Devices & Instruments company?
A good GF Score depends on the Medical Devices & Instruments industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Bio-Works Technologies AB and its competitors. Bio-Works Technologies AB's current GF Score is 68, which is 19% above median its own 10-year median of 57.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Works Technologies AB stock overvalued right now?
Based on GuruFocus' analysis, Bio-Works Technologies AB (XSAT:BIOWKS) is currently considered Fairly Valued. The stock's GF Value™ is kr3.62, compared to a current price of kr3.35 — trading 7.5% below its estimated fair value. The current GF Score is 68, which is 19% above median its 10-year median of 57.00. Bio-Works Technologies AB's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Bio-Works Technologies AB (XSAT:BIOWKS), the current GF Score is 68 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Works Technologies AB (XSAT:BIOWKS) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Works Technologies AB stock appears to be undervalued.
The current stock price of kr3.35 is trading 7.5% below its estimated GF Value™ of kr3.62.
GuruFocus considers Bio-Works Technologies AB to be Fairly Valued.
Key valuation signals for XSAT:BIOWKS:
GF Score: 68 (19% above median its 10-year median of 57.00)
GF Value™: kr3.62 vs. price of kr3.35 (7.5% below fair value)
No single metric tells the full story. See the XSAT:BIOWKS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Works Technologies AB is a Sweden-based life science company which is engaged in designing, developing, manufacturing and supplying products for purification and separation of proteins and other molecules. The product line of the company includes activated resin, immobilized metal-ion affinity chromatography resin, ion exchange chromatography resin, size exclusion chromatography resin and others. The company has also developed affinity chromatography technique, BabyBio Columns, OptiBio glass columns for separating proteins, and protein purification. Bio-Works serves various end users such as academic research laboratories, biopharmaceutical companies, the food and beverage industry and others.
68GF Score
Get the complete analysis for XSAT:BIOWKS
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:BIOWKS has been successfully added to your 
